BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22055460)

  • 1. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade.
    Zha X; Hu Z; He S; Wang F; Shen H; Zhang H
    Cancer Lett; 2011 Dec; 313(2):211-7. PubMed ID: 22055460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Livers with constitutive mTORC1 activity resist steatosis independent of feedback suppression of Akt.
    Kenerson HL; Subramanian S; McIntyre R; Kazami M; Yeung RS
    PLoS One; 2015; 10(2):e0117000. PubMed ID: 25646773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.
    Gao Y; Gartenhaus RB; Lapidus RG; Hussain A; Zhang Y; Wang X; Dan HC
    Mol Cancer Res; 2015 Dec; 13(12):1602-14. PubMed ID: 26374334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
    Zhang HH; Huang J; Düvel K; Boback B; Wu S; Squillace RM; Wu CL; Manning BD
    PLoS One; 2009 Jul; 4(7):e6189. PubMed ID: 19593385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
    Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
    Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
    Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
    J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
    Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
    J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
    Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
    Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSC1 controls distribution of actin fibers through its effect on function of Rho family of small GTPases and regulates cell migration and polarity.
    Ohsawa M; Kobayashi T; Okura H; Igarashi T; Mizuguchi M; Hino O
    PLoS One; 2013; 8(1):e54503. PubMed ID: 23355874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A complex interplay between Akt, TSC2 and the two mTOR complexes.
    Huang J; Manning BD
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):217-22. PubMed ID: 19143635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways.
    Feng Z; Hu W; de Stanchina E; Teresky AK; Jin S; Lowe S; Levine AJ
    Cancer Res; 2007 Apr; 67(7):3043-53. PubMed ID: 17409411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1.
    Zhou J; Brugarolas J; Parada LF
    Hum Mol Genet; 2009 Nov; 18(22):4428-41. PubMed ID: 19692352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition.
    Han EK; Leverson JD; McGonigal T; Shah OJ; Woods KW; Hunter T; Giranda VL; Luo Y
    Oncogene; 2007 Aug; 26(38):5655-61. PubMed ID: 17334390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
    Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
    PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase.
    Das F; Ghosh-Choudhury N; Dey N; Mandal CC; Mahimainathan L; Kasinath BS; Abboud HE; Choudhury GG
    J Biol Chem; 2012 Feb; 287(6):3808-22. PubMed ID: 22184110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer.
    Iliopoulos D; Jaeger SA; Hirsch HA; Bulyk ML; Struhl K
    Mol Cell; 2010 Aug; 39(4):493-506. PubMed ID: 20797623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TSC1 activates TGF-β-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition.
    Thien A; Prentzell MT; Holzwarth B; Kläsener K; Kuper I; Boehlke C; Sonntag AG; Ruf S; Maerz L; Nitschke R; Grellscheid SN; Reth M; Walz G; Baumeister R; Neumann-Haefelin E; Thedieck K
    Dev Cell; 2015 Mar; 32(5):617-30. PubMed ID: 25727005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.
    Lacher MD; Pincheira R; Zhu Z; Camoretti-Mercado B; Matli M; Warren RS; Castro AF
    Oncogene; 2010 Dec; 29(50):6543-56. PubMed ID: 20818424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
    Astle MV; Hannan KM; Ng PY; Lee RS; George AJ; Hsu AK; Haupt Y; Hannan RD; Pearson RB
    Oncogene; 2012 Apr; 31(15):1949-62. PubMed ID: 21909130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.